CN114288427A - Gastrointestinal tract oral CT contrast agent - Google Patents
Gastrointestinal tract oral CT contrast agent Download PDFInfo
- Publication number
- CN114288427A CN114288427A CN202210196062.9A CN202210196062A CN114288427A CN 114288427 A CN114288427 A CN 114288427A CN 202210196062 A CN202210196062 A CN 202210196062A CN 114288427 A CN114288427 A CN 114288427A
- Authority
- CN
- China
- Prior art keywords
- contrast agent
- oral
- gastrointestinal tract
- contrast
- gastrointestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 29
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000002496 gastric effect Effects 0.000 claims abstract description 8
- 244000068988 Glycine max Species 0.000 claims abstract description 7
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 7
- 240000008415 Lactuca sativa Species 0.000 claims abstract description 7
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 7
- 239000008213 purified water Substances 0.000 claims abstract description 7
- 235000012045 salad Nutrition 0.000 claims abstract description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 6
- 235000013373 food additive Nutrition 0.000 claims abstract description 6
- 239000002778 food additive Substances 0.000 claims abstract description 6
- 229960001025 iohexol Drugs 0.000 claims abstract description 6
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 6
- 239000003755 preservative agent Substances 0.000 claims abstract 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical group [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 6
- 235000010241 potassium sorbate Nutrition 0.000 claims description 6
- 239000004302 potassium sorbate Substances 0.000 claims description 6
- 229940069338 potassium sorbate Drugs 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- 239000005452 food preservative Substances 0.000 claims description 2
- 235000019249 food preservative Nutrition 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 abstract description 7
- 229960004537 ioversol Drugs 0.000 abstract description 7
- 238000013170 computed tomography imaging Methods 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 238000002601 radiography Methods 0.000 abstract description 3
- 238000002591 computed tomography Methods 0.000 description 23
- 238000003304 gavage Methods 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960005133 diatrizoate meglumine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Abstract
The invention discloses an oral gastrointestinal CT contrast agent, which comprises, by mass, 0.5-1.5% of edible liquid paraffin, 0.5-1.5% of soybean salad oil, 0.5-1.5% of sodium carboxymethylcellulose, 0.1-0.3% of food additives, 0.1-0.2% of preservatives, 0.5-1% of ioversol or iohexol, and the balance of purified water. The invention can obviously improve the gastrointestinal tract radiography performance, prolong the CT imaging time of the contrast agent, effectively improve the diagnosis efficiency of doctors, reduce the problem of re-taking a large amount of water and the contrast agent, reduce the economic burden of patients and prevent the body of the patients from generating uncomfortable conditions.
Description
Technical Field
The invention belongs to the technical field of CT (computed tomography) contrast examination, and particularly relates to an oral gastrointestinal CT contrast agent.
Background
When the X-ray examination is carried out on the human abdomen, the internal organs of the abdomen are more and the tissue density is similar, and the CT contrast medium which is harmless to the human body is required to be introduced to improve the contrast of the gastrointestinal tract or focus, so that the ideal diagnosis and examination effect can be achieved.
The diatrizoate meglumine or ioversol which is commonly used in clinic is mixed with drinking water to be used for assisting gastrointestinal tract CT radiography, because a large amount of time is consumed in the process of CT examination and the process of waiting for examination of a patient, the diatrizoate meglumine or ioversol is mixed with the drinking water to be used for assisting gastrointestinal tract radiography to have short retention time in the gastrointestinal tract, and along with the lapse of time, the CT value is obviously reduced, and the examination efficiency of imaging doctors on gastrointestinal tract diseases can be reduced. In order to ensure the accuracy of the disease examination, the patient can only take a large amount of drinking water and contrast medium again, which not only increases the economic burden of the patient, but also makes the body of the patient uncomfortable.
Disclosure of Invention
The invention aims to provide an oral gastrointestinal CT contrast agent, which meets the clinical requirements and overcomes the defects of the gastrointestinal tract contrast agent.
In order to achieve the purpose, the invention adopts the following technical scheme:
an oral CT contrast agent for gastrointestinal tract comprises (by weight) edible liquid paraffin 0.5-1.5%, soybean salad oil 0.5-1.5%, sodium carboxymethylcellulose 0.5-1%, food additive 0.1-0.3%, antiseptic 0.1-0.2%, ioversol or iohexol 0.5-1%, and purified water in balance
Preferably, the food additive is xylitol.
Preferably, the food preservative is potassium sorbate.
Compared with the prior art, the invention has the beneficial effects that:
the contrast agent can obviously improve the gastrointestinal tract contrast performance, prolong the CT imaging time of the contrast agent, effectively improve the diagnosis efficiency of doctors, reduce the problem of re-taking a large amount of water and the contrast agent, reduce the economic burden of patients and prevent the uncomfortable condition of the bodies of the patients.
Drawings
FIG. 1 is a CT image before gavage in a rabbit gavage experiment in the gastrointestinal tract oral CT contrast medium of the invention.
FIG. 2 is a CT image of example 1 in a rabbit gavage experiment with an oral gastrointestinal CT contrast medium of the present invention.
FIG. 3 is an image of a comparative example in a rabbit gavage experiment in an oral gastrointestinal CT contrast medium of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments 1 to 3 and the comparative examples in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1:
an oral CT contrast agent for gastrointestinal tract is prepared from edible liquid paraffin 1%, soybean salad oil 1%, sodium carboxymethylcellulose 0.6%, xylitol 0.15%, potassium sorbate 0.15%, ioversol or iohexol 0.5%, and purified water in balance.
Example 2:
an oral CT contrast agent for gastrointestinal tract comprises (by weight) edible liquid paraffin 0.5%, soybean salad oil 0.5%, sodium carboxymethylcellulose 0.5%, xylitol 0.1%, potassium sorbate 0.1%, ioversol or iohexol 1%, and purified water in balance.
Example 3:
an oral CT contrast agent for gastrointestinal tract is prepared from edible liquid paraffin 1.5%, soybean salad oil 1.5%, sodium carboxymethylcellulose 1%, xylitol 0.3%, potassium sorbate 0.15%, ioversol 0.75 or iohexol, and purified water in balance.
Comparative example:
the preparation is carried out according to a published contrast agent formula which comprises the following steps: the weight percentage is edible liquid paraffin 1%, soybean salad oil 1%, acacia gum 0.7%, purified water 97%, food additive 0.3% (aspartame, potassium sorbate).
Test example:
the oral contrast agents obtained from the above four embodiments were sampled and tested, and the test data obtained from the samples are as follows:
1) the HU values were determined by CT imaging of four groups of samples with a CT imager, the results are shown in the graph:
| name of item | Example 1 | Example 2 | Example 3 | Comparative example |
| CT (HU) value | 124.6 | 135.7 | 132.1 | -27.9 |
2) The rabbit gavage experiment is carried out, imaging analysis and display are carried out by utilizing CT imaging contrast agents, and the results are shown in a graph:
| experimental project | Before gastric lavage | Example 1 (gavage)Rear) | Comparative example (after gavage) |
| CT (HU) value | 67.6 | 154.6 | 128.2 |
3) The experiment of gavage is carried out four rabbits respectively, makes four rabbits correspond a set of sample in proper order and irritates the stomach to carry out the discontinuity to four groups of experiment contrast group CT values and detect, obtain experimental data, as follows:
in summary, the following steps: the invention can obviously improve the performance of the oral contrast agent, can effectively improve the CT contrast performance by adding the iodophorol in the oral contrast agent, and can prolong the contrast stabilization time to 4-6 hours, thereby obviously improving the retention time of gastrointestinal tract contrast, further effectively improving the diagnosis efficiency of doctors, reducing the problem of re-taking a large amount of water and the contrast agent and reducing the economic burden of patients.
While embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made herein without departing from the principles of the invention, and it is intended to cover all such modifications, alterations and adaptations that fall within the scope of the invention, as defined by the appended claims.
Claims (3)
1. An oral CT contrast agent for gastrointestinal tracts comprises, by mass, 0.5-1.5% of edible liquid paraffin, 0.5-1.5% of soybean salad oil, 0.5-1.5% of sodium carboxymethylcellulose, 0.1-0.3% of a food additive, 0.1-0.2% of a preservative, 0.5-1% of iohexol and the balance of purified water.
2. The oral gastrointestinal CT contrast medium according to claim 1, wherein the food additive is xylitol.
3. The oral gastrointestinal CT contrast agent according to claim 1, wherein the food preservative is potassium sorbate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210196062.9A CN114288427A (en) | 2022-03-01 | 2022-03-01 | Gastrointestinal tract oral CT contrast agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210196062.9A CN114288427A (en) | 2022-03-01 | 2022-03-01 | Gastrointestinal tract oral CT contrast agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114288427A true CN114288427A (en) | 2022-04-08 |
Family
ID=80978692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210196062.9A Pending CN114288427A (en) | 2022-03-01 | 2022-03-01 | Gastrointestinal tract oral CT contrast agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114288427A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1065595A (en) * | 1991-04-12 | 1992-10-28 | 弗里桑尼斯公司 | But the oil in water emulsion type x-ray contrast agent of the heat sterilization of non-gastrointestinal medication |
| CN1233505A (en) * | 1998-04-24 | 1999-11-03 | 胡挽华 | Enterogastric negative radiography agent and prodn. method therefor |
| CN101698105A (en) * | 2009-11-23 | 2010-04-28 | 侯树君 | Gastrointestinal tract contrast medium |
| US20110311457A1 (en) * | 2007-07-26 | 2011-12-22 | Nanoscan Imaging, Llc | Methods for imaging vascular inflammation using improved nanoparticle contrast agents |
| WO2021206316A1 (en) * | 2020-04-08 | 2021-10-14 | 압타바이오 주식회사 | Agent for treating contrast-induced acute kidney injury |
-
2022
- 2022-03-01 CN CN202210196062.9A patent/CN114288427A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1065595A (en) * | 1991-04-12 | 1992-10-28 | 弗里桑尼斯公司 | But the oil in water emulsion type x-ray contrast agent of the heat sterilization of non-gastrointestinal medication |
| CN1233505A (en) * | 1998-04-24 | 1999-11-03 | 胡挽华 | Enterogastric negative radiography agent and prodn. method therefor |
| US20110311457A1 (en) * | 2007-07-26 | 2011-12-22 | Nanoscan Imaging, Llc | Methods for imaging vascular inflammation using improved nanoparticle contrast agents |
| CN101698105A (en) * | 2009-11-23 | 2010-04-28 | 侯树君 | Gastrointestinal tract contrast medium |
| WO2021206316A1 (en) * | 2020-04-08 | 2021-10-14 | 압타바이오 주식회사 | Agent for treating contrast-induced acute kidney injury |
Non-Patent Citations (1)
| Title |
|---|
| 顾学裘主编: "《药物制剂注解》", vol. 1, 人民卫生出版社, pages: 942 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ulug et al. | Dual ectopic thyroid: report of a case | |
| Roberts et al. | Malabsorption in the horse associated with alimentary lymphosarcoma | |
| Unlu et al. | Substernal goiter: from definitions to treatment | |
| EP1458328B1 (en) | Formulations comprising locust bean gum as stabilizing agent and mannitol as osmotic agent for use in medical or diagnostic procedures | |
| EP0360266B1 (en) | Barium sulfate contrast medium for x-ray examination of the large intestine | |
| van der Gaag et al. | A boxer dog with chronic hypertrophic gastritis resembling Menetrier's disease in man | |
| CN114288427A (en) | Gastrointestinal tract oral CT contrast agent | |
| Ohlerth et al. | Computed tomography of the thorax in calves from birth to 105 days of age | |
| Oliveira et al. | Juvenile polyposis of infancy in a child with deletion of BMPR1A and PTEN genes: surgical approach | |
| Ejaz et al. | Caecal epiploic appendagitis masquerading clinically as an acute appendicitis: a case report and brief literature review | |
| Leshen et al. | Bilateral Morgagni hernia: A unique presentation of a rare pathology | |
| Sackier et al. | Cystic pneumatosis in coeliac disease. | |
| Falerno et al. | Imaging and Endoscopic Diagnosis of Lung Diseases in Small Animals. A Review | |
| Badour et al. | A case of superior mesenteric artery syndrome got physicians in trouble | |
| Silver et al. | Phaeochromocytoma of the bladder | |
| Roediger et al. | Value of small bowel enema in incomplete intestinal obstruction | |
| Shebrya et al. | Role of computed tomography in diagnosis of appendicitis and its complications | |
| Harrison | Contrast Media in Computed Tomography | |
| Yuan et al. | Case Report: Diagnosis and Treatment of a Giant Retroperitoneal Liposarcoma Presenting as an Irreducible Inguinal Hernia | |
| Jayson et al. | Ulcerative Colitis in Patients with Ankylosing Spondylitis [Summary] | |
| CN108514644B (en) | Short T2 effect rectal/vaginal cavity internal magnetic resonance imaging contrast agent and preparation method thereof | |
| Moreira et al. | Patent urachus in primary care: a case report | |
| Han | Ting Gu, Ying-li Lu, Bing Han, Bo-Ren Jiang, Li-Zhen Wang, Li-Zhen Yang & | |
| Bligh | The Radiological Investigation of Hydrosalpinx | |
| Gu et al. | Ectopic thyroids have lower computed tomography attenuation values than orthotopic thyroids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220408 |